Abstract Body

We hypothesized that aminobisphosphonates (N-BPs), such as pamidronate (PAM), zoledronate (Zol) and alendronate (ALN), that inhibit the formation of farnesyl pyrophosphate groups, used for protein prenylation disrupting cell signaling, may induce reversal of HIV latency. Therefore, here we explore their potential as novel latency reversing agents.

Latency reactivation capacity of N-BPs was analyzed ex vivo in nine HIV-seropositive individuals on suppressive antiretroviral therapy (ART). Resting CD4 T cells were isolated and left untreated or treated with PHA, PAM or Zol, and then cell-associated HIV RNA (caRNA) levels and replication-competent HIV were measured. RNA-seq was used to explore the N-BPs’ mechanism of action, and flow cytometry was used to analyze the ex vivo effect of N-BPs on immune cell activation and proliferation. Longitudinal PBMC (baseline and weeks 2, 24, 48 post intervention) were obtained from the ACTG A5163. This trial examined the effects of weekly dosing of ALN or placebo (PLB) on low bone density associated with HIV and ART. We measured caRNA levels and total HIV DNA levels. A Wilcoxon matched-pairs signed-rank test was used to analyze patient-specific replicate data across treatment types, and a Mann-Kendall test was used to test for time trend (in either direction) in HIV DNA levels.

N-BPs induced reactivation of latent HIV ex vivo (Figure 1A) without causing non-specific activation or other significant alterations on peripheral immune cell populations. RNA-seq analysis showed a correlation between pathways altered by N-BP treatment and those altered following HIV infection (R=0.44, p<0.001). In vivo administration of ALN induced perturbations of the latent reservoir in 8 of 9 participants analyzed who took ALN, that were not detected in participants who took PLB (N=5). Most importantly, treatment with N-BP ALN resulted in a 2.9 to 49.1-fold decrease in total HIV DNA levels in three of eight participants (Figure 1B), while no changes were detected in the PLB arm.

We present the first demonstration that N-BPs can reactivate latent HIV in primary CD4 T cells and show that, in vivo, N-BPs can function as latency reversing agents and significantly reduce total DNA levels. These findings, together with the known safety profile of N-BPs, support the need for further clinical testing of N-BPs to reduce persistent HIV infection in vivo.